ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0039.5

Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases

Haruka Takahashi1, Hiroaki Hatano2, Masahiro Nakano3, Haruka Tsuchiya4, Mineto Ota4, Tomohisa Okamura5, Keishi Fujio4 and Kazuyoshi Ishigaki6, 1Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences and Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 3Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 6RIKEN, Tokyo, Japan

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Autoinflammatory diseases, cytokines, Gene Expression

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Abnormal cytokine regulation is the fundamental pathology of immune-mediated diseases (IMDs). Clinical transcriptome data has a potential to monitor real-time cytokine pathway activities of each IMD patient and guide treatment choices. However, multiple confounders including immunosuppressive therapies and experimental batch effects obscures the biologically relevant signals underlying clinical transcriptome data. The aim of this study is i) to establish an analytical strategy to accurately quantify cytokine pathway activities excluding the confounder effects and ii) elucidate the similarity and dissimilarity across 10 immune-related diseases by applying our strategy to the clinical transcriptome database.

Methods: We utilized the ImmuNexUT database, the largest open-access database of clinical transcriptome data with 28 FACS-sorted immune cell subsets obtained from 10 IMDs: SLE, idiopathic inflammatory myopathy (IIM), SSc, MCTD, SS, RA, Behcet’s disease (BD), adult-onset Still’s disease (AOSD), ANCA-associated vasculitis (AAV), and Takayasu arteritis (TAK) (Figure 1). Using the combination of supervised and unsupervised approaches, we learned the cytokine-induced transcriptome alterations from a large-scale in-vitro cultured fibroblast experiments stimulated by eight cytokines: IFN-α, IFN-γ, TNF-α, IL-1β, IL-6/sIL-6R, IL-17, IL-18 and TGF-β1 (n=506 samples in total). We then transferred the knowledge to the clinical transcriptome data. To mitigate the different statistical power due to unbalanced sample sizes across 10 IMDs, we applied the multivariate adaptive shrinkage approach.

Results: We first took an unsupervised approach and conducted the principal component analysis (PCA) of the cytokine-stimulated fibroblast datasets to learn the transcriptome axes reflecting multiple cytokine signatures. We then projected clinical transcriptome data onto the PC space and confirmed that IMDs were separated by cytokine signatures, with a pronounced shift in SLE. We next took a supervised approach and detected the IMD- and cytokine-related transcriptome signatures from both datasets. By jointly analyzing both signatures simultaneously, we successfully characterized the transcriptome similarity and dissimilarity across 10 immune-related diseases from a viewpoint of cytokine-related signatures. The cytokine signatures grouped IMDs into two clusters: the autoimmune diseases (MCTD, SLE, IIM, SSc, RA and SS) and autoinflammatory diseases (BD, AAV, and TAK).

Conclusion: Our new analytical strategy successfully detected cytokine-related transcriptome characteristics of 10 IMDs, which would be a foundation to elucidate the IMD pathology.

Supporting image 1

Figure 1. The overview of datasets and analytical strategies.
We analyzed transcriptome data of 10 immune-related diseases using the knowledge obtained from transcriptome data of cytokine stimulated fibroblasts. We utilized both unsupervised and supervised approaches.

Disclosures: H. Takahashi: None; H. Hatano: None; M. Nakano: None; H. Tsuchiya: None; M. Ota: Chugai, 12, MO belonged to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceu; T. Okamura: Chugai Pharmaceutical., 12, belong to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical.; K. Fujio: AbbVie/Abbott, 6, Asahi Kasei, 5, 6, Astellas, 6, AstraZeneca, 6, Ayumi, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai Pharmaceutical., 5, 6, Daiichi-Sankyo, 6, Eisai, 5, 6, Eli Lilly, 5, 6, Janssen, 6, Novartis, 6, Ono, 6, Pfizer, 6, Sanofi, 6, Tanabe Mitsubishi, 5, 6, Tsumura, 5; K. Ishigaki: None.

To cite this abstract in AMA style:

Takahashi H, Hatano H, Nakano M, Tsuchiya H, Ota M, Okamura T, Fujio K, Ishigaki K. Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cytokine-induced-transcriptome-modification-elucidates-the-similarity-and-dissimilarity-across-10-immune-related-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokine-induced-transcriptome-modification-elucidates-the-similarity-and-dissimilarity-across-10-immune-related-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology